Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.

The company's shares are trading at their lowest since August 2023. Source: xStation
Rivian Automotive: Rising star or a meteorite?
US OPEN: Valuations under pressure amid deregulation spree
DE40: DAX gains 0.5%📈Lufthansa surges almost 5% amid Kepler recommendation
Broadcom shares drop 5% despite robust earnings and AI demand 🗽